AMRI to produce polymers for Revolymer in Wales

Published: 10-Nov-2011
Manufacturing

Rev7, AGC and other polymers are components of degradable gum products


AMRI, a global contract services organisation, has signed an agreement with Revolymer, a UK-based technology development company, to become its primary manufacturer and supplier of Rev7, AGC and other polymers. These polymers are the main components of Revolymer’s Rev7 degradable gum products.

This new three-year deal expands an existing relationship between the two firms.

Under the agreement, AMRI will produce the specified polymers at its facility in Wales, UK using patented technology licensed from Revolymer.

  • Companies:
  • Curia
See more

You may also like

Manufacturing

CDMO Curia Global refinances to drive global growth

Read more
The R&D/manufacturing specialist will refinance its senior secured credit facilities to capitalise on market opportunities within the biopharma industry

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

CDMO Curia Global refinances to drive global growth

The R&D/manufacturing specialist will refinance its senior secured credit facilities to capitalise on market opportunities within the biopharma industry
Manufacturing

Curia recognised on India Pharma Outlook’s 2023 List of top 10 CDMO companies

Curia, a leading contract research, development and manufacturing organisation, has been recognised as one of the top 10 CDMOs in India by India Pharma Outlook
Manufacturing

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

The company was recognised in providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy
Manufacturing

Curia reveals continuous-flow collaboration with Corning

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs
Manufacturing

Curia adopts the Berkeley Lights platform

The partnership will expand its antibody discovery capabilities
Manufacturing

Curia enters cooperative agreement with US government to expand sterile fill-finish capability

Curia, formerly AMRI, a leading contract research, development and manufacturing organisation, announces a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the US Army Contracting Command to support the domestic production of injectable medicines
Manufacturing

US government to support Curia fill-finish expansion

“This agreement assures our ability to meet urgent demands for the supply of critical medicines well into the future,” said Curia Chairman and CEO, John Ratliff
Subscribe now